EXoPERT Joins Johnson & Johnson’s JLABS TMC to Advance AI Cancer Diagnostics
EXoPERT has joined JLABS TMC, part of Johnson & Johnson’s global incubator network, announced in a press release. The Houston-based biotechnology company develops AI-powered exosome-based liquid biopsy diagnostics for early cancer detection.
As a JLABS resident, EXoPERT gains access to infrastructure, resources, and partnerships across the pharmaceutical, biotechnology, and medical technology sectors. The company aims to advance clinical validation of its platform, which integrates high-purity exosome isolation, surface-enhanced Raman spectroscopy, and AI-driven molecular analysis to enable non-invasive detection of early-stage cancers.
EXoPERT is collaborating with institutions including Johns Hopkins University School of Medicine, City of Hope, and several U.S. Department of Veterans Affairs medical centers. These partnerships will support evaluation of the platform’s performance across diverse patient populations and assist in moving toward regulatory approval.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Taiwanese Health Technology Groups Test US Market in Dallas
AstraZeneca and Oracle Partner on AI for Clinical Trials
Orakl Oncology Raises $34 Million to Predict Cancer Drug Response With AI
Illumina Adds Three Research Tools to BioInsight Platform
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Daily AI Brief: the AI news that matters, in your inbox.